Imago BioSciences, Inc.

Biotechnology ResearchCalifornia, United States11-50 Employees

Our scientific efforts are aimed at developing drugs that improve the management of proliferative diseases of the bone marrow. Our clinical focus is on acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis and essential thrombocythemia. These diseases share several features. They are diseases caused by acquired mutations in blood stem cells. To varying degrees, these mutations drive excessive growth of bone marrow cells, as well as alter their function. For example, myelofibrosis can be viewed as a chronic inflammatory disorder in which inflammatory cytokines and growth factors cause bone marrow cells to alter the architecture of and ultimately destroy the bone marrow.
Imago BioSciences has developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role in regulating the growth and development of bone marrow cells. Our first clinical inhibitor of LSD1, bomedemstat (or IMG-7289) is being studied in patients with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms including myelofibrosis. Future clinical studies are planned for other related diseases.

Sign up for free to view info

Email Format Employee directory